Yuan et al. studied the responsiveness of 165 patients with advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms and found the p53 Pro allele carriers had higher response rate than non-carriers (OR = 2.46; 95% CI = 1.11 - 5.45) (34). Here, TP53 is linked to non-small cell lung carcinoma.